Comparative Pharmacology
Head-to-head clinical analysis: CORDRAN N versus NITROFURANTOIN MACROCRYSTALLINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORDRAN N versus NITROFURANTOIN MACROCRYSTALLINE.
CORDRAN N vs NITROFURANTOIN MACROCRYSTALLINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cordran N contains flurandrenolide, a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive actions by inducing phospholipase A2 inhibitory proteins (lipocortins) and modulating gene expression; neomycin is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit.
Nitrofurantoin is reduced by bacterial flavoproteins to reactive intermediates that inhibit multiple bacterial enzymes involved in carbohydrate metabolism, including acetyl-CoA synthetase, and disrupt cell wall synthesis.
Apply sparingly to affected area 2-3 times daily. Use for no longer than 2 weeks.
100 mg orally twice daily for 5-7 days (uncomplicated UTI); 100 mg orally every 12 hours for 10-14 days (pyelonephritis: not first-line).
None Documented
None Documented
Approximately 1-2 hours. Short half-life consistent with topical use; systemic exposure minimal with proper application.
Terminal half-life: 20-60 minutes (short, requires q6h dosing for therapeutic efficacy).
Primarily renal (biliary/fecal minimal). Unchanged drug and glucuronide metabolites excreted in urine.
Renal: 30-40% excreted unchanged in urine. Biliary/fecal: minimal; remainder metabolized or eliminated via other routes.
Category C
Category D/X
Topical Corticosteroid + Antibiotic
Antibiotic